Chemours

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Chemical Solutions segment refers to the sale of chemicals used in industrial and consumer applications in the Americas. The company was founded on February 18, 2014, and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chemours overcomes Q4 challenges, eyes growth and sustainability in 2023

Chemours had a tough Q4 but a successful year overall, with a focus on margin improvement, growth in key businesses, and addressing legacy issues. The company is optimistic about 2023, emphasizing sustainability-led growth and returning value to shareholders.

Chemours reports strong Q1 performance, navigates challenges, eyes growth opportunities

Chemours' Q1 2023 Earnings Call highlighted strong performance, reaffirmed guidance, and emphasized margin improvement strategies. The company faces challenges from macroeconomic uncertainties and inflationary pressures but sees opportunities in sustainable initiatives and market-led innovation. Chemours remains confident in its full-year outlook and growth strategies.

Chemours reports record results, eyes cost reduction and innovation

Chemours had a strong quarter with record results and notable achievements in facility closures and settlements. While challenges lie ahead with a weaker second half expected, the company remains focused on shareholder value and strategic priorities. Opportunities in cost reduction, innovation, and market leadership position Chemours for future growth.

Chemours addresses challenges, eyes growth in sustainable solutions market

Chemours Company navigated challenges in Q3 2023, with a focus on long-term shareholder value and strategic transformation for performance improvement.
Strong performance in Performance Solutions and TSS business, alongside cost savings initiatives, position Chemours for future growth and margin recovery.
Management's commitment to driving value for shareholders amidst industry challenges underscores a proactive approach to addressing market dynamics.

Chemours reports Q4 sales growth, addresses TiO2 market challenges

Chemours is navigating challenges in the TiO2 market while focusing on cost reduction and growth opportunities in other segments. The company aims to maintain competitiveness through strategic decisions and investments in R&D. Analysts' inquiries during the earnings call highlighted concerns about leadership stability and various segment dynamics.

Chemours reports mixed Q1 results, eyes sequential growth in 2024

Chemours' Q1 2024 performance reflected mixed results across segments, with a focus on cost efficiencies, transformation plans, and maintaining liquidity amidst declining net sales and EBITDA.
Despite challenges in certain segments and market uncertainties, Chemours remains optimistic about sequential growth in the second quarter, aiming for significant EBITDA potential in 2024 and long-term financial improvement.
Strategic strengths in cost management, growth initiatives, and market opportunities position Chemours to navigate challenges, drive growth, and enhance profitability in a dynamic business environment.

Chemours exceeds volume expectations amidst challenges, anticipates sequential decline

Chemours demonstrated resilience and growth in key product lines despite facing challenges in Q1 and Q2.
The company's cost-saving efforts and recovery in certain segments highlight its ability to adapt to market conditions.
While financial results were impacted by one-time costs and a decline in net sales, Chemours maintained a strong net leverage ratio.
Anticipated sequential decline in net sales for Q3 underscores the need for strategic planning and operational optimization.

Chemours reports strong Q3 performance amidst strategic growth initiatives

Chemours' Q3 performance reflects operational strength and growth in key segments.
Challenges include declines in net sales for TSS and TT in Q4 and a net loss.
Opportunities exist in cost savings, growth in Opteon refrigerants, and strategic investments.
Overall, Chemours remains confident in its strategy to drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Other. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Other segment consists of performance chemicals and intermediates business. The company was founded on February 18, 2014, and is headquartered in Wilmington, DE.

An investigation has found that the Teflon maker's top executives shifted cash flows at year-end to hit targets that determined their annual stock and bonus awards.

Chemours Executives Improperly Shifted Deals to Boost Pay, Probe Finds

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

CC ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of The Chemours Company Shareholders Who Lost Money

LOS ANGELES, CA / ACCESSWIRE / March 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against The Chemours Company and Encourages Investors with Losses to Contact the Firm

WILMINGTON, Del.--(BUSINESS WIRE)--As previously disclosed, the Audit Committee of the Board of Directors of The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), with the assistance of independent outside counsel, has been overseeing an internal review. The review relates to an anonymous report made to the Chemours Ethics Hotline regarding the matters described below. A substantially complete report of the findings of the internal review was delivered to the full Board on March 5, 202.

Chemours Provides Update on Internal Review

NEW YORK--(BUSINESS WIRE)---- $CC #Investigation--The law firm of Kirby McInerney LLP continues its investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning whether Chemours and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On February 13, 2024, Chemours disclosed that it was postponing the release of its financial results and conference ca.

CC INVESTIGATION ALERT: Kirby McInerney LLP Continues Investigation on Behalf of The Chemours Company Investors

NEW YORK , March 5, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Chemours Company (NYSE: CC) resulting from allegations that Chemours may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Chemours securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

CC INVESTOR ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages The Chemours Company Investors to Inquire About Securities Class Action Investigation - CC

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

CC ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your The Chemours Company investment

CC ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by The Chemours Company

NEW YORK , March 4, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Chemours Company (NYSE: CC) resulting from allegations that Chemours may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Chemours securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

CC LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages The Chemours Company Investors to Inquire About Securities Class Action Investigation - CC

NEW YORK--(BUSINESS WIRE)--Labaton Keller Sucharow, an award-winning shareholder rights firm, is investigating potential violations of the federal securities laws on behalf of investors of The Chemours Company (NYSE: CC) (“Chemours”). Chemours is a global chemical manufacturer headquartered in Wilmington, Delaware. On February 13, 2024, Chemours announced that it would be delaying the release of its fourth quarter and full year 2023 financial results as the Company evaluates its internal contro.

Renowned Litigation Firm Labaton Keller Sucharow LLP is Investigating The Chemours Company for Securities Violations and Encourages Investors to Contact the Firm

NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company ("Chemours" or the "Company") (NYSE: CC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of The Chemours Company - CC

Chemours delayed issuance of its financial reports for Q4 and 2023 this morning. Management warned that when it does report, it will report a loss.

Why Chemours Stock Crashed 37% This Morning

MILWAUKEE , Feb. 29, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Chemours (NYSE: CC). The investigation results from inaccurate statements Chemours may have made regarding its accounting, business operations and prospects.

Ademi LLP Investigates Claims of Securities Fraud against The Chemours Company

Chemours CEO, CFO, and key personnel placed on administrative leave pending internal review. Company discloses potential weaknesses in internal controls, leading to delayed year-end reporting. Chemours experiences a significant decline in stock price, but potential for overreaction and undervaluation. I consider the company interesting, and I will show you why.

Chemours: The Case Amidst Board Trouble, I Say Buy The Weakness

The company's board has also placed both its CEO and CFO on administrative leave.

Chemours Craters. Accounting Issues Delay Earnings.

Chemours (NYSE: CC ) stock is falling on Thursday after the company announced executive changes as it undergoes an internal review from the Audit Committee of the Board of Directors. The big news here is CEO Mark Newman, senior vice president and Chief Financial Officer Jonathan Lock, as well as vice president, controller and Principal Accounting Officer Camela Wisel being placed on administrative leave.

Why Is Chemours (CC) Stock Down 36% Today?

Shares the chemicals company fell sharply in premarket trading after a trio of executives were put on administrative leave amid an internal review of accounting practices and delayed its fourth-quarter earnings report.

Chemours Shares Slide Premarket as Execs on Leave Amid Probe

WILMINGTON, Del.--(BUSINESS WIRE)--Eleventh paragraph, first and second sentences of release dated February 28, 2024 should read: At December 31, 2023, the Company maintained cash and cash equivalents of $1.2 billion; it has restricted cash and restricted cash equivalents of $604 million primarily relating to the U.S. public water district settlement. The updated release reads: CHEMOURS ANNOUNCES MANAGEMENT ACTIONS AND DELAY OF FORM 10-K; PROVIDES PRELIMINARY UNAUDITED 2023 YEAR-END RESULTS The.

CORRECTING and REPLACING Chemours Announces Management Actions and Delay of Form 10-K; Provides Preliminary Unaudited 2023 Year-End Results

WILMINGTON, Del.--(BUSINESS WIRE)--The Board of Directors of The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) has appointed Denise Dignam as the Interim Chief Executive Officer and Matt Abbott as the Interim Chief Financial Officer (principal financial and accounting officer). Ms. Dignam joined Chemours in 2015 and has served as our President – Titanium Technologies since March 2023 and previously served as our President – Advanced Performance Materials from 2021 to 2023. She previ.

Chemours Announces Management Actions and Delay of Form 10-K; Provides Preliminary Unaudited 2023 Year-End Results

NEW YORK , Feb. 25, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of The Chemours Company (NYSE: CC) resulting from allegations that Chemours may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Chemours securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL TRIAL COUNSEL, Encourages The Chemours Company Investors to Inquire About Securities Class Action Investigation - CC

WILMINGTON, Del.--(BUSINESS WIRE)--The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, today announces two upcoming changes to its Board of Directors. Director Sandra Phillips Rogers has announced her decision not to stand for reelection and will serve out the remainder of her current term. Pamela Fletcher will join the Chemours Board as a director,.

Chemours Announces Changes to its Board of Directors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of The Chemours Company (NYSE: CC) resulting from allegations that Chemours may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Chemours securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

CC LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages The Chemours Company Investors to Inquire About Securities Class Action Investigation – CC

OAKLAND, Calif.--(BUSINESS WIRE)---- $CC #CC--Gibbs Law Group is investigating potential legal claims on behalf of Chemours Company (NYSE: CC) investors. Call (888) 410-2925.

Lost Money in The Chemours Company? Gibbs Law Group Investigates Potential Securities Law Violations

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Chemours investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities la.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of The Chemours Company (CC) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company's possible violations of federal securities laws. On February 13, 2024, after the market closed, Chemours disclosed that it was postponing the release of its financial results and conference call related to its fourth quarter and full year 2023. The Company further clarified, stating that it was dela.

News for Chemours Stock (CC)